Magni, Ruben
Rruga, Fatlum
Alsaab, Fahad M.
Sharif, Sara
Howard, Marissa
Espina, Virginia
Kim, Brianna
Lepene, Benjamin
Lee, Gwenyth
Alayouni, Mohamad A.
Steinberg, Hannah
Araujo, Robyn
Kashanchi, Fatah
Riccardi, Fabio
Morreira, Sargento
Araujo, Antonia
Poli, Fernando
Jaganath, Devan
Semitala, Fred C.
Worodria, William
Andama, Alfred
Choudhary, Alok
Honnen, William J.
Petricoin, Emanuel F. III
Cattamanchi, Adithya
Colombatti, Raffaella
de Waard, Jacobus H.
Oberhelman, Richard
Pinter, Abraham
Gilman, Robert H.
Liotta, Lance A.
Luchini, Alessandra
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01AI136722, R21AI138135)
Bill and Melinda Gates Foundation Global Health Program (OPP1198385)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21HD097472)
Article History
Received: 11 March 2020
Accepted: 30 July 2020
First Online: 18 August 2020
Change Date: 27 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-98304-1
Competing interests
: LAL, AL, and EFP are inventors on patents US9012240 and US8497137 related to the affinity particles, and AP and AC are inventors on a pending patent describing the A194 antibody. Ceres Nanosciences (Nanotrap) licensed the technology from George Mason University Research Foundation. LAL, EFP and AL own shares of Ceres Nanosciences. B.L., B.K. are Ceres Nanosciences’ employees who manufactured some reagents for this study. The other authors declare no competing interests.